IL206

IL206 is a preclinical-stage small molecule degrader, specifically a proteolysis-targeting chimera (PROTAC), designed to target Cyclin K for the treatment of solid tumors. Developed by Ildong Pharmaceutical and its R&D subsidiary Yunovia in collaboration with Lead, IL206 induces the selective degradation of Cyclin K via the ubiquitin-proteasome system. Cyclin K is a critical regulatory subunit for cyclin-dependent kinases CDK12 and CDK13, which are essential for RNA polymerase II-mediated transcriptional elongation of DNA damage response genes. By depleting Cyclin K, IL206 effectively inhibits the activity of these kinases, leading to transcriptional stress, cell cycle arrest, and apoptosis in tumor cells.